yohimbine/obesity

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

Paj 1 soti nan 48 rezilta yo

Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Low caloric diet is a commonly accepted treatment in obesity. However, owing to moderate results, a pharmacological support has been proposed. As some efficacious drugs activate overall sympathetic activity, they might modify functions of the cardiovascular system. Three groups of subjects were

A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The search for drugs with anorectic activity, acting within the adrenergic system has attracted the interest of researchers. Partial α2-adrenoceptor agonists might offer the potential for effective and safe treatment of obesity. We compared the effectiveness and safety of α2-adrenoceptor ligands in

Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Multiple behavioral and neurochemical abnormalities are found in the genetically obese mouse, obob , including hyperphagia, elevated hypothalamic norepinephrine (NE) levels, and increases alpha-1 receptor density. The obese mutant also responds abnormally to neuropharmacological agents. In the

Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Oral yohimbine administration (0.2 mg/kg) induced lipid mobilization (increase in plasma non-esterified fatty acids, NEFA) in fasting non-obese women (body mass index BMI = 20.2 +/- 0.5, age 35.5 +/- 2.7 years) without significant action on plasma glucose, insulin levels, heart rate or blood

Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The effect of ephedrine, a non-selective adrenoreceptor agonist, and yohimbine, a selective alpha 2-adrenolytic drug, on gastric emptying of a radiolabelled solid meal was examined in groups of 8 (all women) and 15 (4 men and 11 women) obese patients, respectively. Patients were given orally,

Cardiovascular changes after treatment with dexfenfluramine and yohimbine in obese women measured by thoracic electrical bioimpedance.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

An anorectic drug, dexfenfluramine (dF) is commonly used in obesity treatment. The aim of our study was to investigate if dexfenfluramine used alone or together with alpha 2-adrenolitic yohimbine (Y), can change cardiovascular state in obese women.

[Evaluation of the effect of yohimbine, an alpha2 adrenolytic drug, on gastric emptying in obesity].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In 15 obese subjects (11 women and 4 men) the effect was assessed of yohimbine, an alpha 2-adrenolytic drug on gastric emptying after solid food. After oral administration of 15 mg of the drug no significant change was observed in this emptying in relation to placebo.

[Lack of efficacy of yohimbine in the treatment of obesity].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

There is some evidence that blockade of alpha 2-adrenoceptors on adipocytes may lead to an increase in lipolysis, We have therefore carried out a double blind comparative study of the effects of the selective alpha 2-antagonist yohimbine in human obesity. Nineteen obese volunteers participated in

Yohimbine attenuates clonidine-induced feeding and macronutrient selection in genetically obese (ob/ob) mice.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Biochemical abnormalities in the hypothalamus of the genetically obese (C57B1/6J, ob/ob) mouse, including increased levels of endogenous norepinephrine (NE) in the paraventricular nucleus (PVN) and reduced medial hypothalamic NE metabolism, have been cited as evidence of a CNS defect contributing to

The alpha-2 adrenoceptor antagonist yohimbine does not facilitate weight loss but blocks adrenaline induced platelet aggregation in obese subjects.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Use of yohimbine, an alpha-adrenolytic drug, in obesity].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Neuropeptide Y in obese women during treatment with adrenergic modulation drugs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The aim of the study is the assessment whether weight loss treatment with adrenergic modulation drugs modifies neuropeptide Y (NPY) plasma concentration in obese women. METHODS 13 obese women (BMI 38.3 +/- 4.4) were tested before and subsequently 10 and 20 days after weight loss

Regional differences in adrenoceptor binding and fat cell lipolysis in obese, postmenopausal women.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In women there is an increase in visceral obesity, subcutaneous abdominal adipocyte lipolysis, and risk of cardiovascular disease (CVD) associated with weight gain after menopause. The mechanisms underlying this increase in adrenoreceptor (AR)-agonist catecholamine-stimulated lipolysis and abdominal

Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

As compared to subcutaneous adipocytes, visceral adipocytes have high basal lipolysis, are highly sensitive to catecholamines, and are poorly sensitive to insulin; these traits are amplified when visceral adipocytes hypertrophy. As a result, enlarged visceral fat stores tend to flood the portal

Effects of alpha- and beta-adrenergic stimulation on free magnesium concentrations in platelets from healthy and obese individuals.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We performed this study to investigate whether alpha- and beta-adrenergic agonists are able to regulate intracellular free magnesium concentrations [Mg2+]i in platelets from healthy and obese individuals. Twenty-six informed-consent men (14 healthy and 12 obese) were enrolled in the study. We

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye